Medicine
Guanfacine 2 mg tablet
Guanfacine 2 mg tablet is a generic prescription medicine for oral use, made by 17 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20º to 25 ºC (68 º to 77 ºF).
Key facts
- Active ingredient (INN)
- Guanfacine
- Brand
- Sold under the generic name
- Strength
- 2 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 1000 tablets, 500 tablets and 23 more
- Manufacturers
- Ajanta PharmaIndiaAurobindo PharmaIndiaUnichem LaboratoriesIndiaAdvagen PharmaAmneal PharmaceuticalsRemedyrepackXiromedA2A Integrated PharmaceuticalsActavis PharmaAmneal Pharmaceuticals of New York
- Origin register
- US FDA, United States
- Storage
- Store at 20º to 25 ºC (68 º to 77 ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C02AC02 Guanfacine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 October 1995
- Identifiers
- RxCUI 197745, 197746DailyMed set ID 73d50917-c807-4213-8efe-aea209845936, fa7ae501-ee34-4e50-9052-7952e36bbd0e, 4248d53e-4dc3-452b-96f8-5d715c254c26 +16NDC 53746-713, 62135-728, 70518-4488 +16Application ANDA075109, ANDA216399, ANDA217293 +7
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 27241-243-01 | Ajanta PharmaIndia | 27 April 2023 |
| 100 tablet in 1 bottle | 59651-841-01 | Aurobindo PharmaIndia | 7 August 2023 |
| 100 tablet in 1 bottle | 29300-459-01 | Unichem LaboratoriesIndia | 5 April 2021 |
| 100 tablet in 1 bottle | 73141-019-04 | A2A Integrated Pharmaceuticals | 8 April 2025 |
| 100 tablet in 1 bottle | 0591-0453-01 | Actavis Pharma | 17 October 1995 |
| 1000 tablet in 1 bottle | 72888-124-00 | Advagen Pharma | 1 October 2021 |
| 100 tablet in 1 bottle | 72888-124-01 | Advagen Pharma | 1 October 2021 |
| 500 tablet in 1 bottle | 72888-124-05 | Advagen Pharma | 1 October 2021 |
| 30 tablet in 1 bottle | 72888-124-30 | Advagen Pharma | 1 October 2021 |
| 30 tablet in 1 bottle | 65162-713-03 | Amneal Pharmaceuticals | 25 November 1998 |
| 100 tablet in 1 bottle | 65162-713-10 | Amneal Pharmaceuticals | 25 November 1998 |
| 500 tablet in 1 bottle | 65162-713-50 | Amneal Pharmaceuticals | 25 November 1998 |
| 100 tablet in 1 bottle | 53746-713-01 | Amneal Pharmaceuticals of New York | 15 April 2022 |
| 90 tablet in 1 bottle | 62135-728-90 | Chartwell RX | 12 July 2023 |
| 100 tablet in 1 bottle | 42806-296-01 | Epic Pharma | 30 May 2019 |
| 100 tablet in 1 bottle | 72319-019-04 | i3 Pharmaceuticals | 31 October 2022 |
| 100 tablet in 1 bottle | 24979-199-01 | TWi Pharmaceuticals | 1 September 2022 |
| 100 tablet in 1 bottle | 70700-302-01 | Xiromed | 24 February 2024 |
| 500 tablet in 1 bottle | 70700-302-05 | Xiromed | 24 February 2024 |
| 30 tablet in 1 bottle | 70700-302-30 | Xiromed | 24 February 2024 |
| 30 tablet in 1 blister pack | 70518-3516-0 | Remedyrepack | 13 September 2022 |
| 30 tablet in 1 blister pack | 70518-4488-0 | Remedyrepack | 30 September 2025 |
| 30 tablet in 1 blister pack | 70518-4564-0 | Remedyrepack | 3 February 2026 |
| 50 blister pack in 1 box, unit-dose / 1 tablet in 1 blister pack | 50268-374-15 | AvPAK | 7 June 2017 |
| 30 tablet in 1 blister pack | 67046-1655-3 | Coupler | 28 January 2026 |
| 100 tablet in 1 bottle | 72603-269-01 | Northstar RX | 15 July 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Guanfacine
Clinical summary
Guanfacine is a central alpha-2 adrenergic agonist indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Guanfacine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GuanfacineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Intuniv prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Intuniv: European public assessment report (EPAR) · European Medicines Agency
- Paxneury: European public assessment report (EPAR) · European Medicines Agency
Need Guanfacine 2 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.